➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
McKinsey
AstraZeneca
Johnson and Johnson
McKesson

Last Updated: May 14, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MAVENCLAD

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Mavenclad

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04121403 Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) Recruiting Göteborg University Phase 3 2019-10-01 The main aim and overall objective of the study is to assess whether rituximab is non-inferior to cladribine for the treatment of relapsing MS. Secondly, the investigators will test specific blood and MRI biomarkers that may contribute to future personalized treatment for MS patients. Furthermore, the investigators want to evaluate the health economic consequences of the two therapies.
NCT04121403 Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) Recruiting Helse Forde Phase 3 2019-10-01 The main aim and overall objective of the study is to assess whether rituximab is non-inferior to cladribine for the treatment of relapsing MS. Secondly, the investigators will test specific blood and MRI biomarkers that may contribute to future personalized treatment for MS patients. Furthermore, the investigators want to evaluate the health economic consequences of the two therapies.
NCT04121403 Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) Recruiting Helse Stavanger HF Phase 3 2019-10-01 The main aim and overall objective of the study is to assess whether rituximab is non-inferior to cladribine for the treatment of relapsing MS. Secondly, the investigators will test specific blood and MRI biomarkers that may contribute to future personalized treatment for MS patients. Furthermore, the investigators want to evaluate the health economic consequences of the two therapies.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mavenclad

Condition Name

Condition Name for Mavenclad
Intervention Trials
Multiple Sclerosis 5
Advanced Multiple Sclerosis 1
Relapsing Multiple Sclerosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Mavenclad
Intervention Trials
Multiple Sclerosis 6
Sclerosis 5
Multiple Sclerosis, Chronic Progressive 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Mavenclad

Trials by Country

Trials by Country for Mavenclad
Location Trials
Norway 10
Austria 2
Italy 2
Spain 2
France 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Mavenclad
Location Trials
New York 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Mavenclad

Clinical Trial Phase

Clinical Trial Phase for Mavenclad
Clinical Trial Phase Trials
Phase 4 4
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Mavenclad
Clinical Trial Phase Trials
Not yet recruiting 4
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Mavenclad

Sponsor Name

Sponsor Name for Mavenclad
Sponsor Trials
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany 2
EMD Serono 2
Vestre Viken Hospital Trust 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Mavenclad
Sponsor Trials
Other 20
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Boehringer Ingelheim
AstraZeneca
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.